Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

18 evidence topics · 18 sources

Stage at diagnosis and five-year relative survival by stage, SEER 21, 2016 to 2022
Stage at diagnosisPercent of cases5-year relative survival
In situ“50%”“98.0%”
Localized“34%”“73.0%”
Regional“7%”“41.8%”
Distant“6%”“9.6%”
Unknown“3%”“50.8%”